Publicación:
Pvmsp8 as a novel plasmodium vivax malaria sero-marker for the peruvian amazon
Pvmsp8 as a novel plasmodium vivax malaria sero-marker for the peruvian amazon
No hay miniatura disponible
Fecha
2021
Autores
Villasis E.
Garro K.
Rosas-Aguirre A.
Rodriguez P.
Rosado J.
Gave A.
Guzman-Guzman M.
Manrique P.
White M.
Speybroeck N.
Título de la revista
Revista ISSN
Título del volumen
Editor
MDPI AG
Proyectos de investigación
Unidades organizativas
Número de la revista
Abstracto
The measurement of recent malaria exposure can support malaria control efforts. This study evaluated serological responses to an in-house Plasmodium vivax Merozoite Surface Protein 8 (PvMSP8) expressed in a Baculovirus system as sero-marker of recent exposure to P. vivax (Pv) in the Peruvian Amazon. In a first evaluation, IgGs against PvMSP8 and PvMSP10 proteins were measured by Luminex in a cohort of 422 Amazonian individuals with known history of Pv exposure (monthly data of infection status by qPCR and/or microscopy over five months). Both serological responses were able to discriminate between exposed and non-exposed individuals in a good manner, with slightly higher performance of anti-PvMSP10 IgGs (area under the curve AUC = 0.78 [95% CI = 0.72–0.83]) than anti-PvMSP8 IgGs (AUC = 0.72 [95% CI = 0.67–0.78]) (p = 0.01). In a second evaluation, the analysis by ELISA of 1251 plasma samples, collected during a population-based cross-sectional survey, confirmed the good performance of anti-PvMSP8 IgGs for discriminating between individuals with Pv infection at the time of survey and/or with antecedent of Pv in the past month (AUC = 0.79 [95% CI = 0.74–0.83]). Anti-PvMSP8 IgG antibodies can be considered as a good biomarker of recent Pv exposure in low-moderate transmission settings of the Peruvian Amazon. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Descripción
Palabras clave
PvMSP8,
Antibodies,
ELISA,
Luminex,
Malaria,
P. vivax